Thymic neuroendocrine neoplasms are rare tumours, but their management can often be highly problematic. While previously assumed to be essentially variants of bronchopulmonary (lung) carcinoids, they are generally more aggressive and more difficult to treat. Some 25% are associated with multiple endocrine neoplasia-1, while a higher proportion are associated with the ectopic ACTH syndrome, and occasionally both. We discuss the classification of these tumours, their biology as far as is known, and their clinical, biochemical and imaging features. We also review possible management options and suggest stratagems to optimise their treatment, which even today is far from optimal.

1.
Gaur P, Leary C, Yao JC: Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg 2010;251:1117-1121.
2.
Shimosato Y, Mukai K: Tumors of the Mediastinum, ed 3. Washington, Armed Forces Institute of Pathology, 1995.
3.
Rosai J, Levine G, Weber WR, Higa E: Carcinoid tumors and oat cell carcinomas of the thymus. Pathol Annu 1976;11:201-226.
4.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2015.
5.
Strobel P, Zettl A, Shilo K, Chuang WY, Nicholson AG, Matsuno Y, Gal A, Laeng RH, Engel P, Capella C, Marino M, Chan JK, Rosenwald A, Travis W, Franks TJ, Ellenberger D, Schaefer IM, Marx A: Tumor genetics and survival of thymic neuroendocrine neoplasms: a multi-institutional clinicopathologic study. Genes Chromosomes Cancer 2014;53:738-749.
6.
Moran CA, Suster S: Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol 2000;114:100-110.
7.
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, Guerrera F, Detterbeck F: Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. J Thorac Cardiovasc Surg 2015;149:103-109.e102.
8.
Crona J, Bjorklund P, Welin S, Kozlovacki G, Oberg K, Granberg D: Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre. Lung Cancer 2013;79:289-293.
9.
Cardillo G, Rea F, Lucchi M, Paul MA, Margaritora S, Carleo F, Marulli G, Mussi A, Granone P, Graziano P: Primary neuroendocrine tumors of the thymus: a multicenter experience of 35 patients. Ann Thorac Surg 2012;94:241-245; discussion 245-246.
10.
Ahn S, Lee JJ, Ha SY, Sung CO, Kim J, Han J: Clinicopathological analysis of 21 thymic neuroendocrine tumors. Korean J Pathol 2012;46:221-225.
11.
Fazio N, Milione M: Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications. Cancer Treat Rev 2016;50:61-67.
12.
Filosso PL, Ruffini E, Lausi PO, Lucchi M, Oliaro A, Detterbeck F: Historical perspectives: the evolution of the thymic epithelial tumors staging system. Lung Cancer 2014;83:126-132.
13.
Masaoka A, Monden Y, Nakahara K, Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-2492.
14.
Suster S, Moran CA: Thymic carcinoma: spectrum of differentiation and histologic types. Pathology 1998;30:111-122.
15.
Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P: The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014;9:S65-S72.
16.
Zhao Y, Shi J, Fan L, Yang J, Hu D, Zhao H: Evaluation of the proposed International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancies Interest Group (ITMIG) staging revisions in thymic well-differentiated neuroendocrine carcinoma patients. Eur J Cardiothorac Surg 2016;49:569-573.
17.
Garcia-Yuste M, Matilla JM, Cueto A, Paniagua JM, Ramos G, Canizares MA, Muguruza I: Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007;31:192-197.
18.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
19.
de Laat JM, Pieterman CR, van den Broek MF, Twisk JW, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD: Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. J Clin Endocrinol Metab 2014;99:3325-3333.
20.
Ruffini E, Oliaro A, Novero D, Campisi P, Filosso PL: Neuroendocrine tumors of the thymus. Thorac Surg Clin 2011;21:13-23, v.
21.
Soga J, Yakuwa Y, Osaka M: Evaluation of 342 cases of mediastinal/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg 1999;5:285-292.
22.
Litvak A, Pietanza MC: Bronchial and thymic carcinoid tumors. Hematol Oncol Clin North Am 2016;30:83-102.
23.
Wick MR, Scott RE, Li CY, Carney JA: Carcinoid tumor of the thymus: a clinicopathologic report of seven cases with a review of the literature. Mayo Clin Proc 1980;55:246-254.
24.
Wilkinson S, Teh BT, Davey KR, McArdle JP, Young M, Shepherd JJ: Cause of death in multiple endocrine neoplasia type 1. Arch Surg 1993;128:683-690.
25.
Bhosale P, Shah A, Wei W, Varadhachary G, Johnson V, Shah V, Kundra V: Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. Eur Radiol 2013;23:400-407.
26.
Ferolla P, Falchetti A, Filosso P, Tomassetti P, Tamburrano G, Avenia N, Daddi G, Puma F, Ribacchi R, Santeusanio F, Angeletti G, Brandi ML: Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab 2005;90:2603-2609.
27.
Gibril F, Chen YJ, Schrump DS, Vortmeyer A, Zhuang Z, Lubensky IA, Reynolds JC, Louie A, Entsuah LK, Huang K, Asgharian B, Jensen RT: Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003;88:1066-1081.
28.
Shepherd JJ: The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Arch Surg 1991;126:935-952.
29.
Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Menegaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Delemer B, Beckers A, Bonithon-Kopp C: Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010;34:249-255.
30.
Singh Ospina N, Thompson GB, C Nichols F 3rd, Cassivi SD, Young WF Jr: Thymic and bronchial carcinoid tumors in multiple endocrine neoplasia type 1: The Mayo Clinic Experience from 1977 to 2013. Horm Cancer 2015;6:247-253.
31.
Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
32.
Otake Y, Aoki M, Nakanishi T, Hashimoto K: Atypical carcinoid of thymus associated with multiple endocrine neoplasia syndrome type 1. Gen Thorac Cardiovasc Surg 2010;58:534-537.
33.
Lim LC, Tan MH, Eng C, Teh BT, Rajasoorya RC: Thymic carcinoid in multiple endocrine neoplasia 1: genotype-phenotype correlation and prevention. J Intern Med 2006;259:428-432.
34.
Christakis I, Qiu W, Silva Figueroa AM, Hyde S, Cote GJ, Busaidy NL, Williams M, Grubbs E, Lee JE, Perrier ND: Clinical features, treatments, and outcomes of patients with thymic carcinoids and multiple endocrine neoplasia type 1 syndrome at MD Anderson Cancer Center. Horm Cancer 2016;7:279-287.
35.
Sakurai A, Imai T, Kikumori T, Horiuchi K, Okamoto T, Uchino S, Kosugi S, Suzuki S, Suyama K, Yamazaki M, Sato A: Thymic neuroendocrine tumour in multiple endocrine neoplasia type 1: female patients are not rare exceptions. Clin Endocrinol (Oxf) 2013;78:248-254.
36.
Meinardi JR, Wolffenbuttel BH, Dullaart RP: Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol 2007;157:245-254.
37.
Alexandraki KI, Grossman AB: The ectopic ACTH syndrome. Rev Endocr Metab Disord 2010;11:117-126.
38.
Neary NM, Lopez-Chavez A, Abel BS, Boyce AM, Schaub N, Kwong K, Stratakis CA, Moran CA, Giaccone G, Nieman LK: Neuroendocrine ACTH-producing tumor of the thymus - experience with 12 patients over 25 years. J Clin Endocrinol Metab 2012;97:2223-2230.
39.
Trott MJ, Farah G, Stokes VJ, Wang LM, Grossman AB: A thymic neuroendocrine tumour in a young female: a rare cause of relapsing and remitting Cushing's syndrome. Endocrinol Diabetes Metab Case Rep 2016;2016:160018.
40.
Chen YY, Li SQ, Liu HS, Qin YZ, Li L, Huang C, Bi YL, Meng YX, He J, Zhou XY, Ma DJ: Ectopic adrenocorticotropic hormone syndrome caused by neuroendocrine tumors of the thymus: 30-year experience with 16 patients at a single institute in the People's Republic of China. Onco Targets Ther 2016;9:2193-2201.
41.
Liu RX, Wang WQ, Ye L, Bi YF, Fang H, Cui B, Zhou WW, Dai M, Zhang J, Li XY, Ning G: p21-activated kinase 3 is overexpressed in thymic neuroendocrine tumors (carcinoids) with ectopic ACTH syndrome and participates in cell migration. Endocrine 2010;38:38-47.
42.
Yano M, Fukai I, Kobayashi Y, Mizuno K, Konishi A, Haneda H, Suzuki E, Endo K, Fujii Y: ACTH-secreting thymic carcinoid associated with multiple endocrine neoplasia type 1. Ann Thorac Surg 2006;81:366-368.
43.
Ghazi AA, Dezfooli AA, Mohamadi F, Yousefi SV, Amirbaigloo A, Ghazi S, Pourafkari M, Berney D, Ellard S, Grossman AB: Cushing syndrome secondary to a thymic carcinoid tumor due to multiple endocrine neoplasia type 1. Endocr Pract 2011;17:e92-e96.
44.
Li X, Su J, Zhao L, Wu J, Ding X, Fang F, Wu Y, Sun H, Peng Y: Familial Cushing syndrome due to thymic carcinoids in a multiple endocrine neoplasia type 1 kindred. Endocrine 2014;47:183-190.
45.
Somasundaram NP, Garusinghe C, Berney D, Grossman AB: A thymic carcinoid tumour causing Zollinger-Ellison and Cushing's syndromes due to ectopic ACTH and gastrin secretion. Hormones (Athens) 2013;12:305-308.
46.
Pacak K, Ilias I, Chen CC, Carrasquillo JA, Whatley M, Nieman LK: The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab 2004;89:2214-2221.
47.
Groves AM, Mohan HK, Wegner EA, Hain SF, Bingham JB, Clarke SE: Positron emission tomography with FDG to show thymic carcinoid. AJR Am J Roentgenol 2004;182:511-513.
48.
Xu H, Zhang M, Zhai G, Zhang M, Ning G, Li B: The role of integrated (18)F-FDG PET/CT in identification of ectopic ACTH secretion tumors. Endocrine 2009;36:385-391.
49.
Markou A, Manning P, Kaya B, Datta SN, Bomanji JB, Conway GS: [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing's syndrome. Eur J Endocrinol 2005;152:521-525.
50.
Isidori AM, Sbardella E, Zatelli MC, Boschetti M, Vitale G, Colao A, Pivonello R: Conventional and nuclear medicine imaging in ectopic Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 2015;100:3231-3244.
51.
Morgat C, Velayoudom-Cephise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazere J, Nunes ML, Smith D, Hindie E, Fernandez P, Tabarin A: Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging 2016;43:1258-1266.
52.
Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, Maecke HR, Huszno B, Pach D, Sowa-Staszczak A, Janota B, Szybinski P, Kulig J: 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123-1133.
53.
Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S: (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37:722-727.
54.
Teh BT, Grimmond S, Shepherd J, Larsson C, Hayward N: Multiple endocrine neoplasia type I: clinical syndrome to molecular genetics. Aust N Z J Surg 1995;65:708-713.
55.
Teh BT, Zedenius J, Kytola S, Skogseid B, Trotter J, Choplin H, Twigg S, Farnebo F, Giraud S, Cameron D, Robinson B, Calender A, Larsson C, Salmela P: Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 1998;228:99-105.
56.
Li Y, Peng Y, Jiang X, Cheng Y, Zhou W, Su T, Xie J, Zhong X, Song D, Wu L, Fan L, Li M, Hong J, Wang W, Ning G, Cao Y: Whole exome sequencing of thymic neuroendocrine tumor with ectopic ACTH syndrome. Eur J Endocrinol 2017;176:187-194.
57.
Burgess JR, Giles N, Shepherd JJ: Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2001;55:689-693.
58.
Sadacharan D, Reddy SV, Agrawal V, Agarwal G: Rapid development of thymic neuroendocrine carcinoma despite transcervical thymectomy in a patient with multiple endocrine neoplasia type 1. Indian J Endocrinol Metab 2013;17:743-746.
59.
Tiffet O, Nicholson AG, Ladas G, Sheppard MN, Goldstraw P: A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. Chest 2003;124:141-146.
60.
Song Z, Zhang Y: Primary neuroendocrine tumors of the thymus: clinical review of 22 cases. Oncol Lett 2014;8:2125-2129.
61.
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD: Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 2015;26:1604-1620.
62.
Sugawara K, Mizumoto M, Numajiri H, Ohno T, Ohnishi K, Ishikawa H, Okumura T, Sakurai H: Proton beam therapy for a patient with a giant thymic carcinoid tumor and severe superior vena cava syndrome. Rare Tumors 2014;6:5177.
63.
Oberg K, Hellman P, Ferolla P, Papotti M: Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(suppl 7):vii120-123.
64.
Okabe N, Inoue T, Watanabe Y, Muto S, Hasegawa T, Ohsugi J, Higuchi M, Shio Y, Suzuki H: Two cases of thymic carcinoid treated with octreotide long-acting repeatable (in Japanese). Gan To Kagaku Ryoho 2014;41:879-883.
65.
Dham A, Truskinovsky AM, Dudek AZ: Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report. J Thorac Oncol 2008;3:94-97.
66.
Filosso PL, Actis Dato GM, Ruffini E, Bretti S, Ozzello F, Mancuso M: Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature. J Thorac Cardiovasc Surg 2004;127:1215-1219.
67.
Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Cao CD, Lena H, Berruti A, Buikhuisen W, Stankovic M, Singh N, Chiodini E, Gislimberti G, Oberg K, Baudin E: Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA study (abstract 416O). ESMO 2016 Congr, Copenhagen, October 2016.
68.
Cardillo G, Treggiari S, Paul MA, Carleo F, De Massimi AR, Remotti D, Graziano P, Martelli M: Primary neuroendocrine tumours of the thymus: a clinicopathologic and prognostic study in 19 patients. Eur J Cardiothorac Surg 2010;37:814-818.
69.
Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991.
70.
Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM: Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest 2013;143:955-962.
71.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Delle Fave G, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016;387:968-977.
72.
Lim SH, Lee JY, Sun JM, Kim KM, Ahn JS, Ahn MJ, Park K: A new KIT gene mutation in thymic cancer and a promising response to imatinib. J Thorac Oncol 2013;8:e91-e92.
73.
Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Matano E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V: Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol 2012;69:309-315.
74.
Hamada S, Masago K, Mio T, Hirota S, Mishima M: Good clinical response to imatinib mesylate in atypical thymic carcinoid with KIT overexpression. J Clin Oncol 2011;29:e9-e10.
75.
van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ: Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007;34:1219-1227.
76.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E: Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125-135.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.